Leverage real-world data to change the way you design clinical trials. Improve site selection, identify the right biomarkers and patient populations, and shorten enrollment cycles with on-demand access to the SOPHiA DDM™ Platform and its wealth of clinical data from across the globe.

86% of trials fail to reach enrollment targets on time.

**Patient Identification**

Automate the real-time identification of biomarker-positive patients

**Site Selection**

Identify sites with large cohorts of biomarker-positive patients

**Trial Rescue**

Find additional sites for ongoing trials not meeting enrollment goals

**Benefits of SOPHiA DDM™ Trial Match**

- Empower your decision-making process by tapping into structured on-demand clinical data
- Save precious time by reviewing and assessing key site and patient data on a single platform
- Accelerate enrollment by exploring real-time data from a vast clinical research network spread across 750+ institutions

**Design Biomarker-Driven Trials with SOPHiA DDM™ Trial Match**

- **Identify the genomic biomarker** of interest
- **Generate** a report of sites with biomarker-positive cohorts
- **Get notified** when new patients matching your criteria are found
- **Run a retrospective study** on SOPHiA DDM™
- **Select** the best sites for your clinical trial

**CASE STUDY**

**SOPHiA DDM™ Trial Match Allows the Timely Detection of EGFR ex19del**

EGFR-activating mutations leading to deletions in exon 19 (ex19del) are highly prevalent among NSCLC patients and a major predictor of the response to TKI therapies. The early detection of these alterations by NGS testing could improve prognosis significantly.²

**Key outcomes**

1. SOPHiA DDM™ Trial Match was activated on 2 sites
2. An alert was set to detect patients with EGFR ex19del
3. In only 4 months, the solution identified 43 positive patients
4. Amongst the geographical regions within the scope of the trial, SOPHiA GENETICS had a footprint in 9 countries (36 institutions)


**About SOPHiA GENETICS**

- **750+** Healthcare Institutions
- **70+** Countries
- **1 Million+** Genomic Profiles

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services were used by more than 750 hospitals, laboratories, and biopharma institutions globally in 2021.

Want to learn more?

Or contact us at: info@sophiagenetics.com

© SOPHiA GENETICS 2022 -GL-BP-2200004-r2

The information included in this flyer has been prepared for and is intended for viewing by a global audience. This flyer contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult local sales representatives. All product and company names are trademark™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. SOPHiA DDM™ is for Research Use Only and is not intended for purposes other than research. SOPHiA DDM™ is not for diagnostic, therapeutic, or treatment purposes.